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Clinical features and molecular characterization of 109 
group B streptococci causing neonatal invasive infections 
were determined over an 18-month period in France. Sixty-
four percent of the strains were from late-onset infections, 
and 75% were capsular type III. The hypervirulent clone ST-
17 was recovered in 80% of meningitis cases.
G
roup B Streptococcus (GBS) is the leading cause of in-
fectious illness among newborns. Invasive infections in 
neonates can result in pneumonia, sepsis, or meningitis. Ear-
ly-onset disease (EOD) occurs within the ﬁ  rst week. Late-
onset disease (LOD) occurs after the ﬁ  rst week and accounts 
for most meningitis cases and deaths (1). Because recom-
mendations for intrapartum antibioprophylaxis (IAP) for 
mothers in labor at risk for GBS infection have been widely 
implemented in many countries, the incidence of EOD has 
declined to <1/1,000 births, but the incidence of LOD has re-
mained unchanged (2). To date, 10 capsular serotypes have 
been described (Ia, Ib, and II–IX). Among these, serotype 
III is of particular importance because it is responsible for a 
substantial proportion of EOD and most cases of LOD (3–8). 
Different studies have suggested that most neonatal invasive 
diseases and almost all cases of meningitis are caused by a 
limited number of strains belonging to a homogeneous sero-
type III clone. This clone is deﬁ  ned by multilocus sequence 
typing (MLST) analyses as ST-17, the so-called highly 
virulent clone (4–8). However, data available in Europe are 
limited regarding the distribution of GBS genotypes among 
invasive isolates recovered from neonates. 
We describe clinical characteristics, capsular type, and 
MLST allelic and antimicrobial drug-susceptibility proﬁ  les 
of 109 nonredundant GBS isolates that caused neonatal in-
vasive infections. These isolates were collected during an 
active surveillance performed in France from May 2006 
through December 2007.
The Study
Clinical data on 109 infants up to 4 months of age 
were analyzed. Sepsis was deﬁ  ned as GBS bacteremia in 
the presence of consistent clinical signs and symptoms. 
Meningitis was diagnosed if GBS was recovered from ce-
rebrospinal ﬂ  uid. GBS isolates were identiﬁ  ed by using a 
commercial Lanceﬁ  eld group–speciﬁ  c latex agglutination 
test. Capsular typing was performed by a multiplex PCR 
as described (9), and the hypervirulent ST-17 clone was 
detected by real-time PCR, as reported (6). Susceptibility 
testing, antibiograms, and MICs were performed accord-
ing to Clinical and Laboratory Standards Institute recom-
mendations (www.clsi.org). Antimicrobial drug–resistance 
genes were detected by using the multiplex PCR as de-
scribed (10). Statistical analysis was performed according 
to the Fisher exact and χ2 tests. A p value of <0.05 was used 
as the threshold for statistical signiﬁ  cance.
We studied 109 GBS strains responsible for neona-
tal invasive infections; 36% (n = 39) and 64% (n = 70) 
were responsible for EOD and LOD, respectively (Table). 
Eighty percent of EOD cases occurred during the ﬁ  rst 
24 hours after birth, with a male:female ratio of 0.9; 72% 
were associated with sepsis, and 28% with meningitis. Ma-
ternal cultures obtained in the last 6 weeks before delivery 
were available for 64% of the cases. Positive GBS cultures 
were detected in only 11% of the cases. One death associ-
ated with meningitis occurred in an infant with EOD. A cap-
sular serotype was assigned to all isolates with a distribution 
as follows: types III (61.5%) and Ia (28.2%) were predomi-
nant compared to types Ib (5.1%), II (2.5%), and V (2.5%) 
(Table). Capsular types IV, and VI–IX were not found. EOD 
meningitis GBS strains were of type III in 81.8% of isolates, 
and all these strains were ST-17 positive.
LOD had a male:female ratio of 1.15, and 82.6% of 
cases occurred during the ﬁ  rst 8 weeks of life, with a peak 
(63%) at 4–8 weeks (data not shown). Sepsis occurred in 
27.1% of LOD cases and meningitis in 65.7%. In 5 cases 
of LOD, less frequent manifestations were observed: sepsis 
was associated with parotitis (2 cases), osteomyelitis (1), 
spondylodiscitis (1), and orchitis (1). Three cases (4.5%) of 
recurrent invasive infections were reported. For 2 of these 3 
cases, the ﬁ  rst episode was early meningitis with a relapse 
of meningitis 2–3 weeks later, despite correct antimicrobial 
drug treatment. The third case was a late-onset sepsis that 
relapsed as a sepsis after the infant had received 3 weeks 
of amoxicillin. None of these infants was fed breast milk, 
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route. The death rate for LOD was 14.5%; 90% of deaths 
were associated with meningitis. Capsular type distribution 
of GBS LOD isolates was as follows: type III was large-
ly predominant (83%) compared with types Ia (7.4%), Ib 
(4.5%), and V (1.5%) (Table). Among strains responsible 
for meningitis, 87% were of type III and almost all (92.5%) 
belonged to the hypervirulent ST-17 clone.
All 109 GBS strains tested were susceptible to penicil-
lin (MIC90 0.016 mg/L), amoxicillin (MIC90 0.016 mg/L), 
cefotaxim (MIC90 0.016 μg/mL), imipenem (MIC90 0.032 
μg/mL), rifampin (MIC90  0.032  μg/mL), vancomycin 
(MIC90 0.75 μg/mL), and displayed low-level resistance to 
gentamicin (MIC90 8 μg/mL). Also, 95.5% were resistant 
to tetracycline because of the presence of tet(M) associ-
ated with tet(O) or tet(L) in 3 and 1 strains, respectively. 
Resistance to erythromycin was detected in 13.8% of the 
isolates and was not correlated with the capsular type or 
the onset of disease. Erythromycin resistance was caused 
by the presence of mef(A) (46.6%), erm(A) (26.6%), or 
erm(B) (20%). 
Conclusions
In France, screening of pregnant women for GBS colo-
nization and IAP for women detected positive was imple-
mented in 2001 but, despite these recommendations, EOD 
continues to occur (11). In this report, 36% of cases were 
EOD. For 71% of EOD cases, maternal vaginal screening 
before delivery had not been conducted or was negative 
for GBS, thus likely explaining the persistence of EOD, 
as already suggested by others (12,13). In our study, LOD 
represents the majority of cases (64%), which is consistent 
with ﬁ  ndings in countries where a screening approach, to-
gether with IAP, was adopted (2,11,13).
Clinical symptoms were signiﬁ  cantly associated with 
the time of infection onset: EOD was mostly associated 
with sepsis (72%), whereas LOD was more frequently re-
sponsible for meningitis (65.7%) (p<0.01). Deaths, all as-
sociated with meningitis, were higher in LOD (14.5%) than 
in EOD cases (2.5%).
The predominance of capsular type III among in-
fants with meningitis is well-known (3,5–8,14,15). In our 
study, type III accounted for 83% of LOD and was sig-
niﬁ  cantly associated with meningitis (85.9%; p<0.01) in 
both EOD and LOD. Moreover, the hypervirulent clone 
ST-17 was signiﬁ  cantly predominant among LOD cases 
(75%; p<0.03) and accounted for 93% of GBS type III 
strains responsible for meningitis. This overrepresenta-
tion of ST-17 among invasive neonatal strains is now well 
recognized worldwide and highlights the fact that this 
clone is well adapted to neonate pathogenesis and may 
possesses speciﬁ  c virulence traits that enhance its inva-
siveness in this population (5–8,14,15). Early detection of 
this clone among colonizing strains in pregnant women or 
in neonates at delivery may therefore constitute the basis 
for developing new prevention strategies. An attractive 
alternative to IAP is vaccinating young women to subse-
quently protect neonates against GBS infections. Conju-
gate vaccines composed of capsular polysaccharides and 
tetanus toxoid have already been evaluated (1). Recent 
studies have suggested that protein antigens induce pro-
tective immunity in animal models, and surface proteins 
common to many strains would have a potential role in 
vaccine development (1). For this reason immunogenic 
antigens speciﬁ  c to the ST-17 clone should be considered 
in designs of future vaccine. 
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